Tafenoquine paediatric


Product vision
  • Product targeting prevention of relapse for P. vivax
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Tafenoquine
  • Single-dose treatment in children who cannot take the adult tablet
  • Final dose regimen/weight banding to be confirmed based on paediatric study final analysis
  • Efficacy in adults established. Pharmacokinetic bridging strategy to establish paediatric dose

Key features
  • Single-dose treatment to prevent relapse of P. vivax malaria
  • Contraindicated in G6PD deficiency
  • Quantitative testing for G6PD deficiency required

  • Clarity around continued role for primaquine (G6PD-deficient patients)

  • Paediatric pharmacokinetics bridging study recruitment was completed October 2019

Next milestone
  • Paediatric pharmacokinetics bridging study readout

MMV Project Director
  • Dr Isabelle Borghini